TD Cowen analyst Phil Nadeau initiates coverage on Lakefront Biotherapeutics (NASDAQ: LKFT) with a Buy rating.The analyst comments "We are ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage